Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARHGAP16P is classified as a human pseudogene that resembles the functional gene ARHGAP16, which belongs to the family of Rho GTPase activating proteins (RhoGAPs). Unlike functional RhoGAPs, ARHGAP16P does not encode a protein, lacks functional domains, and has no known physiological or pathological significance[1][3][7]. Pseudogenes generally arise from gene duplication or retrotransposition events and are often transcriptionally silent or produce non-functional RNA. In contrast, bona fide RhoGAPs such as ARHGAP16 are involved in signaling pathways regulating cytoskeletal organization, cell motility, and immune modulation, and are sometimes implicated in cancer progression and immune processes[1][5][7]. However, these activities do not apply to ARHGAP16P. ARHGAP16P should not be considered a therapeutic target and is not a member of any canonical molecular or therapeutic classification.
Null. Mechanisms of action for interacting drugs are not relevant, as ARHGAP16P has no protein product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho GTPase activating protein 16, pseudogene (ARHGAP16P).